[ad_1]
By IOL Reporter 
6h ago
Cape Town – A total of 1,422 new Covid-19-related cases have been identified in South Africa.
The cumulative number of Covid-19 cases now stands at 1,548,157, Health Minister Zweli Mkhize said in a statement Wednesday night. A total of 756 new cases of Covid-19 were reported on Tuesday and 548 on Monday.
A total of 58 more deaths from Covid-19 have been reported (compared to 78 yesterday): Gauteng 23, KwaZulu-Natal 23, Western Cape 9, Northern Cape 2 and Free State 1. No deaths were recorded in Eastern Cape, Limpopo , Mpumalanga and Northwest.
The death toll from Covid-19 is now 52,846. Cumulative recoveries have risen to 1,474,319, representing a 95% recovery rate.
The cumulative total of tests performed is 9,879,348, with 34,513 tests completed since the last report.
Visiting hours at Gauteng government hospitals have been reduced to allow one visitor per patient for 15 minutes.
“The amendment will allow family and friends of patients to spend time with loved ones while adhering to non-pharmaceutical Covid-19 measures such as social distancing and minimizing hospital overcrowding and congestion,” the health department said. provincial.
Several restaurants in KwaZulu-Natal gained Green Flag status on Wednesday when their existing Covid-19 protocols were certified by the newly formed GreenFlag Association.
Much like the Blue Flag status earned for beaches, the GreenFlag certification of public spaces is said to offer an assurance that a venue has taken every precaution to provide a safe public space to patrons and staff, especially when Try adequate ventilation.
Pfizer Inc and BioNTech SE said Wednesday that their Covid-19 vaccine was safe and effective and produced robust antibody responses in children ages 12 to 15, paving the way for them to apply for emergency use authorization in the US. weeks.
Pfizer hopes the group’s vaccines can begin before next school year, Albert Bourla, Pfizer president and CEO, said in a statement.
Pfizer’s vaccine is already licensed for use in people 16 years of age and older. The new study offers the first evidence of how the vaccine will also work in school-age adolescents.
In the trial of 2,260 adolescents aged 12-15 years, there were 18 cases of Covid-19 in the group that received a placebo injection and none in the group that received the vaccine, resulting in 100% efficacy in prevention of Covid-19.
The vaccine was well tolerated, with side effects similar to those seen among 16 to 25-year-olds in the adult trial. It did not list side effects for the younger group, but the adult trial side effects were generally mild to moderate and included injection site pain, headaches, fever and fatigue.
MESS
[ad_2]
